Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy.
Journal: Oncotarget
Published: August 06, 2017
Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.
Journal: Molecular cancer therapeutics
Published: February 10, 2017
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
Journal: Oncotarget
Published: December 30, 2015
Aldehyde Dehydrogenase 1B1 as a Modulator of Pancreatic Adenocarcinoma.
Journal: Pancreas
Published: November 14, 2015
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.
Journal: International journal of cancer
Published: November 23, 2014
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Journal: International journal of cancer
Published: May 27, 2014
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma.
Journal: Investigational new drugs
Published: February 19, 2014
Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.
Journal: British journal of cancer
Published: June 14, 2013
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.
Journal: Cancer medicine
Published: June 04, 2012
Last Updated: 09/26/2026